Clinical Trial Detail

NCT ID NCT03739606
Title Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors City of Hope Medical Center
Indications

hematologic cancer

Hodgkin's lymphoma

chronic myeloid leukemia

acute leukemia

hairy cell leukemia

acute lymphoblastic leukemia

Therapies

Flotetuzumab

Age Groups: adult child senior

No variant requirements are available.